Advertisement

Breast Cancer Research and Treatment

, Volume 90, Issue 2, pp 169–185 | Cite as

Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival

  • Steven D. Heys
  • Tarun Sarkar
  • Andrew W. Hutcheon
Review

Abstract

Primary chemotherapy achieves high clinical response rates and facilitates breast conservation in many patients with large and locally advanced breast cancer. It may also serve to indicate responsiveness to chemotherapeutic agents. A pathological complete response to primary chemotherapy is a primary predictor and surrogate marker of long-term outcome, but occurs in only approximately 15% of patients. Docetaxel is of particular interest in this setting. Primary docetaxel chemotherapy has single-agent activity in both dose-dense and traditional schedules, with acceptable tolerability. Furthermore, concomitant docetaxel–anthracycline schedules have shown promise in Phase II trials, achieving clinical overall response rates (ORRs) of 77–96%, pathological complete responses of up to 24%, and breast conservation in up to 89% of patients.

Two Phase III studies have shown that pathological complete response is significantly improved with the addition of docetaxel to anthracycline-based therapy versus the latter alone: the Aberdeen study achieved a rate of 34% versus 16%, respectively (p = 0.04), and the NSABP-B27 study a rate of 26% versus 14%, respectively (p < 0.001). The Aberdeen study has suggested that the addition of docetaxel may yield a survival benefit at 5 years (p = 0.04). The Phase II GEPAR-DUO study hints at a benefit for sequential over concomitant docetaxel-based therapy, with improvements in both clinical response (ORR 87% versus 77%, respectively) and pathological complete response (23% versus 12%, respectively). Non-anthracycline docetaxel-based primary regimens have shown early promise. As we continue to define the optimal regimen, a growing body of evidence supports the use of docetaxel in primary chemotherapeutic regimens for breast cancer.

Keywords

breast cancer docetaxel primary chemotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Forrest, AP, Levack, PA, Chetty, U, Hawkins, RA, Miller, WR, Smyth, JF, Anderson, TJ 1986A human tumour modelLancet2840842PubMedGoogle Scholar
  2. 2.
    Mauriac, L, Durand, M, Avril, A, Dilhuydy, JM 1991Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.Ann Oncol2347354PubMedGoogle Scholar
  3. 3.
    Heys, SD, Eremin, JM, Sarkar, TK, Hutcheon, AW, Ah-See, A, Eremin, O 1994Role of multimodality therapy in the management of locally advanced carcinoma of the breastJ Am Coll Surg179493504PubMedGoogle Scholar
  4. 4.
    Fisher, B, Bryant, J, Wolmark, N, Mamounas, E, Brown, A, Fisher, ER, Wickerham, DL, Begovic, M, DeCillis, A, Robidoux, A, Margolese, RG, Cruz, AB,Jr, Hoehn, JL, Lees, AW, Dimitrov, NV, Bear, HD 1998Effect of preoperative chemotherapy on the outcome of women with operable breast cancerJ Clin Oncol1626722685PubMedGoogle Scholar
  5. 5.
    Smith, IC, Heys, SD, Hutcheon, AW, Miller, ID, Payne, S, Gilbert, FJ, Ah-See, AK, Eremin, O, Walker, LG, Sarkar, TK, Eggleton, SP, Ogston, KN 2002Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxelJ Clin Oncol2014561466CrossRefPubMedGoogle Scholar
  6. 6.
    Ogston, KN, Miller, ID, Payne, S, Hutcheon, AW, Sarkar, TK, Smith, I, Schofield, A, Heys, SD 2003A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survivalBreast12320327PubMedGoogle Scholar
  7. 7.
    Hutcheon, AW, Heys, SD, Sarkar, TK, Ogston, KN, Eremin, O, Walker, LG, Miller, ID 2003Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial.Breast Cancer Res Treat82 (Suppl 1)S9Abstract 11Google Scholar
  8. 8.
    Heys, SD, Hutcheon, AW, Sarkar, TK, Ogston, KN, Miller, ID, Payne, S, Smith, I, Walker, LG, Eremin, O 2002Aberdeen Breast Group: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trialClin Breast Cancer3 (Suppl. 2)S69S74CrossRefGoogle Scholar
  9. 9.
    Chan, S, Friedrichs, K, Noel, D, Pinter, T, Belle, S, Vorobiof, D, Duarte, R, Gil Gil, M, Bodrogi, I, Murray, E, Yelle, L, Minckwitz, G, Korec, S, Simmonds, P, Buzzi, F, Gonzalez Mancha, R, Richardson, G, Walpole, E, Ronzoni, M, Murawsky, M, Alakl, M, Riva, A 1999Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancerJ Clin Oncol1723412354PubMedGoogle Scholar
  10. 10.
    Nabholtz, JM, Falkson, C, Campos, D, Szanto, J, Martin, M, Chan, S, Pienkowski, T, Zaluski, J, Pinter, T, Krzakowski, M, Vorobiof, D, Leonard, R, Kennedy, I, Azli, N, Murawsky, M, Riva, A, Pouillart, P 2003TAX 306 Study Group: docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trialJ Clin Oncol21968975PubMedGoogle Scholar
  11. 11.
    Ravdin, PM, Burris, HA, Cook, G, Eisenberg, P, Kane, M, Bierman, WA, Mortimer, J, Genevois, E, Bellet, RE 1995Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancerJ Clin Oncol1328792885PubMedGoogle Scholar
  12. 12.
    Makris, A, Powles, TJ, Ashley, SE, Chang, J, Hickish, T, Tidy, VA, Nash, AG, Ford, HT 1998A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancerAnn Oncol911791184CrossRefPubMedGoogle Scholar
  13. 13.
    Mauriac, L, MacGrogan, G, Avril, A, Durand, M, Floquet, A, Debled, M, Dilhuydy, JM, Bonichon, F 1999Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS).Ann Oncol104752CrossRefPubMedGoogle Scholar
  14. 14.
    Scholl, SM, Fourquet, A, Asselain, B, Pierga, JY, Vilcoq, JR, Durand, JC, Dorval, T, Palangie, T, Jouve, M, Beuzeboc, P, Pouillart, P 1994Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.Eur J Cancer30A645652CrossRefPubMedGoogle Scholar
  15. 15.
    Semiglazov, VF, Topuzov, EE, Bavli, JL, Moiseyenko, VM, Ivanova, OA, Seleznev, IK, Orlov, AA, Barash, NY, Golubeva, OM, Chepic, OF 1994Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb–IIIa breast cancerAnn Oncol5591595PubMedGoogle Scholar
  16. 16.
    Scholl, SM, Pierga, JY, Asselain, B, Beuzeboc, P, Dorval, T, Garcia-Giralt, E, Jouve, M, Palangie, T, Remvikos, Y, Durand, JC, Fourquet, A, Pouillart, P 1995Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.Eur J Cancer 31A19691975PubMedGoogle Scholar
  17. 17.
    Wolmark, N, Wang, J, Mamounas, E, Bryant, J, Fisher, B 2001Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18J Natl Cancer Inst Monogr3096102PubMedGoogle Scholar
  18. 18.
    Chollet, P, Amat, S, Cure, H, Latour, M, Bouedec, G, Mouret-Reynier, MA, Ferriere, JP, Achard, JL, Dauplat, J, Penault-Llorca, F 2002Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancerBr J Cancer8610411046CrossRefPubMedGoogle Scholar
  19. 19.
    Schelling, M, Avril, N, Nahrig, J, Kuhn, W, Romer, W, Sattler, D, Werner, M, Dose, J, Janicke, F, Graeff, H, Schwaiger, M 2000Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancerJ Clin Oncol1816891695PubMedGoogle Scholar
  20. 20.
    Smith, IC, Welch, AE, Hutcheon, AW, Miller, ID, Payne, S, Chilcott, F, Waikar, S, Whitaker, T, Ah-See, AK, Eremin, O, Heys, SD, Gilbert, FJ, Sharp, PF 2000Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapyJ Clin Oncol1816761688PubMedGoogle Scholar
  21. 21.
    Smith, IC, Miller, ID 2001Issues involved in research into the neoadjuvant treatment of breast cancerAnticancer Drugs12 (Suppl. 1)S25S29Google Scholar
  22. 22.
    Chang, J, Powles, TJ, Allred, DC, Ashley, SE, Clark, GM, Makris, A, Assersohn, L, Gregory, RK, Osborne, CK, Dowsett, M 1999Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancerJ Clin Oncol1730583063PubMedGoogle Scholar
  23. 23.
    Sjostrom, J, Blomqvist, C, Heikkila, P, Boguslawski, KV, Raisanen-Sokolowski, A, Bengtsson, NO, Mjaaland, I, Malmstrom, P, Ostenstadt, B, Bergh, J, Wist, E, Valvere, V, Saksela, E 2000Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancerClin Cancer Res631033110PubMedGoogle Scholar
  24. 24.
    Ellis, PA, Smith, IE, McCarthy, K, Detre, S, Salter, J, Dowsett, M 1997Preoperative chemotherapy induces apoptosis in early breast cancerLancet349849letterPubMedGoogle Scholar
  25. 25.
    Fisher, B, Wolmark, N, Fisher, ER, Deutsch, M 1985Lumpectomy and axillary dissection for breast cancer: surgical, pathological, and radiation considerationsWorld J Surg9692698PubMedGoogle Scholar
  26. 26.
    Bissery, MC, Guenard, D, Gueritte-Voegelstein, F, Lavelle, F 1991Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogueCancer Res5148454852PubMedGoogle Scholar
  27. 27.
    Crown J, J, O’Leary, M 2000The taxanes: an updateLancet35511761178CrossRefPubMedGoogle Scholar
  28. 28.
    Launchbury, AP, Habboubi, N 1993Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicityCancer Treat Rev19197228PubMedGoogle Scholar
  29. 29.
    Bellot, R, Robert, J, Dieras, V, Misset, JL, Baille, P, Bozec, L, Vernillet, L, Riva, A, Azli, N, Pouillart, P 1998Taxotere® does not change the pharmacokinetic (PK) profile of doxorubicin (Dox) or doxorubicinol (Dx-ol)Proc Am Soc Clin Oncol17221a(Abstract 853)Google Scholar
  30. 30.
    Amat, S, Bougnoux, P, Penault-Llorca, F, Fetissof, F, Cure, H, Kwiatkowski, F, Achard, JL, Body, G, Dauplat, J, Chollet, P 2003Primary docetaxel for operable breast cancer induces a high pathological response and breast-conservation rateBr J Cancer8813391345CrossRefPubMedGoogle Scholar
  31. 31.
    Bines, J, Martins, RG, Carmo, PAO, Del Giglio, A, Vasconcelos, A, Cabral, A, Vinholes, J, Gusmao, C 2001Induction chemotherapy with weekly docetaxel (Taxotere®) in unfavourable locally advanced breast cancer (LABC)Eur J Cancer376(Abstract 622)Google Scholar
  32. 32.
    Estévez, L, Cuevas, JM, Anton, A, Florian, J, Lopez-Vega, JM, Velasco, A, Lobo, F, Herrero, A, Fortes, J 2003Weekly docetaxel (Taxotere®) is effective as primary chemotherapy for stage II and III breast cancer. Results of a phase II, multicenter study.Clin Cancer Res9686692PubMedGoogle Scholar
  33. 33.
    Gradishar, WJ 1997Docetaxel as primary chemotherapy in patients with stage III breast cancerOncology11 (Suppl. 8)1518Google Scholar
  34. 34.
    Chevallier, B, Roche, H, Olivier, JP, Chollet, P, Hurteloup, P 1993Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.Am J Clin Oncol16223228PubMedGoogle Scholar
  35. 35.
    Sataloff, DM, Mason, BA, Prestipino, AJ, Seinige, UL, Lieber, CP, Baloch, Z 1995Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcomeJ Am Coll Surg180297306PubMedGoogle Scholar
  36. 36.
    Ganem, G, Tubiana-Hulin, M, Fumoleau, P, Combe, M, Misset, JL, Vannetzel, JM, Bachelot, T, Ybarlucea, LR, Lotz, V, Bendahmane, B, Dieras, V 2003Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancerAnn Oncol1416231628CrossRefPubMedGoogle Scholar
  37. 37.
    Valero, V, Esteva, FJ, Sahin, AA, Booser, DJ, Strom, EA, Esparza-Guerra, LT, Ross, MI, Rosales, MF, Ibrahim, NK, Cirstofanil, M, Buchholz, TA, Hunt, KK, Hortobagyi, GN 2000Phase II trial of primary chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +/- tamoxifen in locally advanced breast cancerBreast Cancer Res Treat6469(Abstract 253)Google Scholar
  38. 38.
    Minckwitz, G, Costa, SD, Eiermann, W, Blohmer, JU, Tulusan, AH, Jackisch, C, Kaufmann, M 1999Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxelJ Clin Oncol1719992005PubMedGoogle Scholar
  39. 39.
    Minckwitz, G, Costa, SD, Raab, G, Blohmer, JU, Eidtmann, H, Hilfrich, J, Merkle, E, Jackisch, C, Gademann, G, Tulusan, AH, Eiermann, W, Graf, E, Kaufmann, M 2001German Preoperative Adriamycin-Docetaxel and German Adjuvant Breast Cancer Study Groups: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb studyJ Clin Oncol1935063515Google Scholar
  40. 40.
    Ferlini, C, Scambia, G, Distefano, M, Filippini, P, Isola, G, Riva, A, Bombardelli, E, Fattorossi, A, Benedetti Panici, P, Mancuso, S 1997Synergistic antiproliferative activity of tamoxifen and docetaxel on three estrogen receptor-negative cancer cell lines is mediated by the induction of apoptosisBr J Cancer75884891PubMedGoogle Scholar
  41. 41.
    Matteis, A, Nuzzo, F, D’Aiuto, G, Labonia, V, Landi, G, Rossi, E, Mastro, AA, Botti, G, Maio, E, Perrone, F 2002Docetaxel plus epidoxorubicin as primary treatment in patients with large operable or locally advanced carcinoma of the breast. A single-center, phase II study.Cancer94895901CrossRefPubMedGoogle Scholar
  42. 42.
    Wenzel, C, Locker, GJ, Schmidinger, M, Rudas, M, Taucher, S, Gnant, MF, Jakesz, R, Steger, GG 2002Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factorAnticancer Drugs136774PubMedGoogle Scholar
  43. 43.
    Luporsi, L, Vanlemmens, L, Coudert, B, Mayer, F, Bonneterre, J, Petit, T, Borel, C, Hirsch, M, Bey, P 20006 cycles of FEC 100 versus 6 cycles of epirubicin–docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (Pts): preliminary results of a randomized phase II trial of Girec S01Proc Am Soc Clin Oncol1992(Abstract 355)Google Scholar
  44. 44.
    Milla, A, Morales, S, Burillo, MA, Borrega, P, Machenes, I, Checa, T, Janariz, J, Illaramendi, JJ, Lizon, J 2001High-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC). An ONCOPAZ and associated hospitals study.Breast Cancer Res Treat69271(Abstract 359)Google Scholar
  45. 45.
    Wenzel, C, Locker, GJ, Pluschnig, U, Zielinski, CC, Rudas, M, Oberhuber, G, Gnant, MF, Taucher, S, Jakesz, R, Steger, GG 2002Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancerCancer Chemother Pharmacol50155159CrossRefPubMedGoogle Scholar
  46. 46.
    Miller, KD, McCaskill-Stevens, W, Sisk, J, Loesch, DM, Monaco, F, Seshadri, R, Sledge, GW,Jr 1999Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology GroupJ Clin Oncol1730333037PubMedGoogle Scholar
  47. 47.
    Minckwitz, G, Raab, G, Schuette, M, Hilfrich, J, Blohmer, JU, Gerber, B, Costa, SD, Merkle, E, Eidtmann, H, Lampe, W, Jackisch, C, duBois, A, Caputo, A, Kaufmann, M,Jr 2002Dose-dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2–3, N0–2 , M0)–primary endpoint analysis of the GEPAR-DUO StudyProc Am Soc Clin Oncol2143a(Abstract 168)Google Scholar
  48. 48.
    Bear, HD, Anderson, S, Brown, A, Smith, R, Mamounas, EP, Fisher, B, Margolese, R, Theoret, H, Soran, A, Wickerham, DL, Wolmark, N 2003National Surgical Adjuvant Breast and Bowel Project Protocol B-27: the effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-27J Clin Oncol2141654174CrossRefPubMedGoogle Scholar
  49. 49.
    Jackisch, C, Minckwitz, G, Eidtmann, H, Costa, SD, Raab, G, Blohmer, JU, Schutte, M, Gerber, B, Merkle, E, Gademann, G, Lampe, D, Hilfrich, J, Tulusan, AH, Caputo, A, Kaufmann, M 2002Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysisClin Breast Cancer3276280PubMedCrossRefGoogle Scholar
  50. 50.
    Hutcheon, AW, Ogston, KN, Heys, SD, Smith, IC, Whitaker, T, Miller, ID, Payne, S, Ah-See, A, Eremin, O, Eggleton, P 2000The Aberdeen Breast Group: primary chemotherapy in the treatment of breast cancer: significantly enhanced clinical and pathological response with docetaxelProc Am Soc Clin Oncol1983a(Abstract 317)Google Scholar
  51. 51.
    Hurley, J, Doliny, P, Gomez, C, Raez, L, Boggs, J, Franco, S, Lee, Y 2000High complete pathologic response rate of locally advanced breast cancers (LABC) to neoadjuvant (NEO) docetaxel and cisplatin chemotherapyProc Am Soc Clin Oncol19127(Abstract 494)Google Scholar
  52. 52.
    Hurley, JE, Doliny, P, Velez, P, Guatam, U, Reis, I, Silva, O, Gomez-Fernandez, C, Lee, Y, Franco, SX 2001High rate of axillary node clearance with neoadjuvant Herceptin, Taxotere, and cisplatin in locally advanced and inflammatory breast cancerBreast Cancer Res Treat69300(Abstract 516)Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Steven D. Heys
    • 1
    • 2
  • Tarun Sarkar
    • 1
  • Andrew W. Hutcheon
    • 1
  1. 1.Departments of Surgery, and Clinical and Medical OncologyUniversity of AberdeenAberdeenUK
  2. 2.Department of SurgeryUniversity Medical BuildingsAberdeenUK

Personalised recommendations